Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent (381 views)
Int J Nanomed (ISSN: 1176-9114, 1178-2013, 1178-2013electronic), 2012; 7: 2007-2017.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.463, 5-year impact factor: 4.027
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84866764636&partnerID=40&md5=19173f929bbc89b03146159878cfb79d
Keywords: Bombesin Peptide, Doxorubicin Delivery, Gastrin-Releasing Peptide Receptors, Pc-3 Cells, Theranostic Applications, 2 Distearoyl Sn Glycero 3 Phosphocholine, Bombesin Receptor, Macrogol, Monomer, Mony Bn, Phospholipid, Unclassified Drug, 2 Distearoyllecithin, 2-Distearoyllecithin, Antineoplastic Agent, Bombesin (7 14), Bombesin (7-14), Drug Carrier, Drug Derivative, Liposome, Pentetic Acid, Peptide Fragment, Phosphatidylcholine, Surfactant, Animal Experiment, Animal Model, Antineoplastic Activity, Article, Binding Affinity, Cancer Cell Culture, Cancer Cell Destruction, Cancer Inhibition, Cell Adhesion, Cell Survival, Chemical Composition, Controlled Study, Cytotoxicity Test, Encapsulation, Female, Human, Human Cell, In Vitro Study, In Vivo Study, Liposomal Delivery, Mouse, Nonhuman, Prostate Cancer, Protein Expression, Protein Localization, Protein Targeting, Tumor Xenograft, Upregulation, Bagg Albino Mouse, Chemistry, Drug Antagonism, Drug Delivery System, Drug Screening, Metabolism, Nanomedicine, Nude Mouse, Pathology, Prostate Tumor, Tumor Cell Line, Inbred Balb C, Prostatic Neoplasms, Surface-Active Agents, Xenograft Model Antitumor Assays,
Affiliations:
*** IBB - CNR ***
CIRPeB, Department of Biological Sciences and IBB CNR, University of Naples 'Federico II', Napoli, Italy
Department of Pharmaceutical Chemistry, University of Naples 'Federico II', Italy
Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione 'G. Pascale', Italy
Department of Experimental Pharmacology, University of Naples 'Federico II', Napoli, Italy
References:
Chabner, B.A., Allegra, C.J., Curt, G.A., Calabresi, P., Antineoplastic agents (1996) Goodman and Gillman's The Pharmacological Basis of Therapeutics, p. 1265. , Hardman JG, Limbird LE, editors. 9th ed. New York: McGraw-Hil
Hortobagyi, G.N., Anthracyclines in the treatment of cancer: An overview (1997) Drugs., 54 (SUPPL. 4), pp. 1-7
Gabizon, A., Martin, F., Polyethylene glycol-coated (pegylated) liposomal doxorubicin: Rationale for use in solid tumours (1997) Drugs., 54 (SUPPL. 4), pp. 15-21
Gabizon, A., Pharmacokinetics of PEGylated liposomal doxorubicin (2003) Clin Pharmacokinet., 42, pp. 419-436
Abraham, S.A., Waterhouse, D.N., Lawrence, D., The liposomal formulation of doxorubicin (2005) Methods Enzymol., 391, pp. 71-97
Tardi, P.G., Boman, N.L., Cullis, P.R., Liposomal doxorubicin (1996) J Drug Target., 4, pp. 129-140
Brown, J.M., Giaccia, A.J., The unique physiology of solid tumours: Opportunities (and problems) for cancer therapy (1998) Cancer Res., 58, pp. 408-1416
Gabizon, A., Catane, R., Uziely, B., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in poly-ethylene-glycol coated liposomes (1994) Cancer Res., 54, pp. 987-992
Gaber, M.H., Wu, N.Z., Hong, K., Huang, S.K., Dewhirst, M.W., Papahadjopoulos, D., Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks (1996) Int J Radiat Oncol Biol Phys., 36, pp. 1177-1187
Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs (1986) Cancer Res., 46, pp. 6387-6392
Marcucci, F., Lefoulon, F., Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress (2004) Drug Discov Today., 9 (5), pp. 219-228
Torchilin, V.P., Antibody-modified liposomes for cancer chemotherapy (2008) Expert Opin Drug Deliv., 5 (9), pp. 1003-1025
Sofou, S., Sgouros, G., Antibody-targeted liposomes in cancer therapy and imaging (2008) Expert Opin Drug Deliv., 5 (2), pp. 189-204
Wu, H.-C., Chang, D.-K., Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy (2010) J Oncol., 2010, pp. 1-8
Reubi, J.C., Waser, B., Schaer, J.C., Laissue, J.A., Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) Eur J Nucl Med., 28 (7), pp. 836-846
Virgolini, I., Raderer, M., Kurtaran, A., Vasoactive intestinal peptidereceptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors (1994) N Engl J Med., 331, pp. 1116-1121
Behr, T.M., Jenner, N., Radetzky, S., Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin (1998) Eur J Nucl Med., 25 (4), pp. 424-430
Breeman, W.A., de Jong, M., Erion, J.L., Preclinical comparison of 111 In-labeled DTPA-or DOTA-bombesin analogs for receptortargeted scintigraphy and radionuclide therapy (2002) J Nucl Med., 43, pp. 1650-1656
Behr, T.M., Gotthardt, M., Barth, A., Behe, M., Imaging tumors with peptidebased radioligands (2001) Q J Nucl Med., 45 (2), pp. 189-200
Accardo, A., Morisco, A., Tesauro, D., Pedone, C., Morelli, G., Naposomes: A new class of peptide derivatized target selective multimodal nanoparticles for imaging and therapeutic applications (2011) Ther Deliv., 2 (2), pp. 235-257
Accardo, A., Tesauro, D., Aloj, L., Peptide containing aggregates as selective nanocarriers for therapeutics (2008) Chem Med Chem., 3, pp. 594-602
Morisco, A., Accardo, A., Tesauro, D., Palumbo, R., Benedetti, E., Morelli, G., Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells (2011) Biopolymers., 96 (1), pp. 88-96
Vaccaro, M., Mangiapia, G., Paduano, L., Structural and relaxometric characterization of peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI (2007) Chem Phys Chem., 8, pp. 2526-2538
Ding, N., Lu, Y., Lee, R.J., Folate receptor-targeted fluorescent paramagnetic bimodal liposomes for tumor imaging (2011) Int J Nanomedicine., 6, pp. 2513-2520
Lammers, T., Aime, S., Hennink, W.E., Storm, G., Kiessling, F., Theranostic nanomedicines (2011) Acc Chem Res., 44 (10), pp. 1029-1038
Accardo, A., Mansi, R., Morisco, A., Peptide modified nanocarriers for selective targeting of bombesin receptors (2010) Mol Biosyst., 6, pp. 878-887
Markwalder, R., Reubi, J.C., Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation (1999) Cancer Res., 59, pp. 1152-1159
Gugger, M., Reubi, J.C., GRP receptors in non-neoplastic and neoplastic human breast (1999) Am J Pathol., 155, pp. 2067-2076
Fleischmann, A., Waser, B., Reubi, J.C., Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms (2007) Cell Oncol., 29, pp. 421-433
Smith, C.J., Volkert, W.A., Hoffman, T.J., Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes (2005) Nucl Med Biol., 32, pp. 733-740
Rogers, B.E., Bigott, H.M., McCarthy, D.W., MicroPET Imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue (2003) Bioconjugate Chem., 14 (4), pp. 756-763
Parry, J.J., Kelly, T.S., Andrews, R., Rogers, B.E., In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties (2007) Bioconjugate Chem., 18 (4), pp. 1110-1117
Schmitt, L., Dietrich, C., Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces (1994) J Am Chem Soc., 116 (19), pp. 8485-8491
Chang, W.C., White, P.D., (2000) Fmoc Solid Phase Peptide Synthesis., , Oxford, UK: Oxford Univ Press
Stewart, J.C.M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate (1980) Anal Biochem., 104, pp. 10-14
Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo (1991) Biochim Biophys Acta Biomembranes., 1066 (1), pp. 29-36
Fritze, A., Hens, F., Kimpfler, A., Schubert, R., Peschka-Süss, R., Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient (2006) Biochimica et Biophysica Acta., 1758 (10), pp. 1633-1640
An, Z., Wang, X., Geller, J., Moossa, A.R., Hoffman, R.M., Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice (1998) Prostate., 34 (3), pp. 169-174
Fridman, R., Kibbey, M.C., Royce, L.S., Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel (1991) J Natl Cancer Inst., 83 (11), pp. 769-774
Xie, J., Lee, S., Chen, X., Nanoparticle-based theranostic agents (2010) Adv Drug Deliv Rev., 62, pp. 1064-1079
Chabner, B. A., Allegra, C. J., Curt, G. A., Calabresi, P., Antineoplastic agents (1996) Goodman and Gillman's The Pharmacological Basis of Therapeutics, p. 1265. , Hardman JG, Limbird LE, editors. 9th ed. New York: McGraw-Hil
Hortobagyi, G. N., Anthracyclines in the treatment of cancer: An overview (1997) Drugs., 54 (SUPPL. 4), pp. 1-7
Abraham, S. A., Waterhouse, D. N., Lawrence, D., The liposomal formulation of doxorubicin (2005) Methods Enzymol., 391, pp. 71-97
Tardi, P. G., Boman, N. L., Cullis, P. R., Liposomal doxorubicin (1996) J Drug Target., 4, pp. 129-140
Brown, J. M., Giaccia, A. J., The unique physiology of solid tumours: Opportunities (and problems) for cancer therapy (1998) Cancer Res., 58, pp. 408-1416
Gaber, M. H., Wu, N. Z., Hong, K., Huang, S. K., Dewhirst, M. W., Papahadjopoulos, D., Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks (1996) Int J Radiat Oncol Biol Phys., 36, pp. 1177-1187
Torchilin, V. P., Antibody-modified liposomes for cancer chemotherapy (2008) Expert Opin Drug Deliv., 5 (9), pp. 1003-1025
Wu, H. -C., Chang, D. -K., Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy (2010) J Oncol., 2010, pp. 1-8
Reubi, J. C., Waser, B., Schaer, J. C., Laissue, J. A., Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) Eur J Nucl Med., 28 (7), pp. 836-846
Behr, T. M., Jenner, N., Radetzky, S., Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin (1998) Eur J Nucl Med., 25 (4), pp. 424-430
Breeman, W. A., de Jong, M., Erion, J. L., Preclinical comparison of 111 In-labeled DTPA-or DOTA-bombesin analogs for receptortargeted scintigraphy and radionuclide therapy (2002) J Nucl Med., 43, pp. 1650-1656
Behr, T. M., Gotthardt, M., Barth, A., Behe, M., Imaging tumors with peptidebased radioligands (2001) Q J Nucl Med., 45 (2), pp. 189-200
Smith, C. J., Volkert, W. A., Hoffman, T. J., Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes (2005) Nucl Med Biol., 32, pp. 733-740
Rogers, B. E., Bigott, H. M., McCarthy, D. W., MicroPET Imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue (2003) Bioconjugate Chem., 14 (4), pp. 756-763
Parry, J. J., Kelly, T. S., Andrews, R., Rogers, B. E., In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin (7-14) analogues containing different amino acid linker moieties (2007) Bioconjugate Chem., 18 (4), pp. 1110-1117
Chang, W. C., White, P. D., (2000) Fmoc Solid Phase Peptide Synthesis., , Oxford, UK: Oxford Univ Press
Stewart, J. C. M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate (1980) Anal Biochem., 104, pp. 10-14
Allen, T. M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo (1991) Biochim Biophys Acta Biomembranes., 1066 (1), pp. 29-36
Int J Nanomed (ISSN: 1176-9114, 1178-2013, 1178-2013electronic), 2012; 7: 2007-2017.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 3.463, 5-year impact factor: 4.027
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-84866764636&partnerID=40&md5=19173f929bbc89b03146159878cfb79d
Keywords: Bombesin Peptide, Doxorubicin Delivery, Gastrin-Releasing Peptide Receptors, Pc-3 Cells, Theranostic Applications, 2 Distearoyl Sn Glycero 3 Phosphocholine, Bombesin Receptor, Macrogol, Monomer, Mony Bn, Phospholipid, Unclassified Drug, 2 Distearoyllecithin, 2-Distearoyllecithin, Antineoplastic Agent, Bombesin (7 14), Bombesin (7-14), Drug Carrier, Drug Derivative, Liposome, Pentetic Acid, Peptide Fragment, Phosphatidylcholine, Surfactant, Animal Experiment, Animal Model, Antineoplastic Activity, Article, Binding Affinity, Cancer Cell Culture, Cancer Cell Destruction, Cancer Inhibition, Cell Adhesion, Cell Survival, Chemical Composition, Controlled Study, Cytotoxicity Test, Encapsulation, Female, Human, Human Cell, In Vitro Study, In Vivo Study, Liposomal Delivery, Mouse, Nonhuman, Prostate Cancer, Protein Expression, Protein Localization, Protein Targeting, Tumor Xenograft, Upregulation, Bagg Albino Mouse, Chemistry, Drug Antagonism, Drug Delivery System, Drug Screening, Metabolism, Nanomedicine, Nude Mouse, Pathology, Prostate Tumor, Tumor Cell Line, Inbred Balb C, Prostatic Neoplasms, Surface-Active Agents, Xenograft Model Antitumor Assays,
Affiliations:
*** IBB - CNR ***
CIRPeB, Department of Biological Sciences and IBB CNR, University of Naples 'Federico II', Napoli, Italy
Department of Pharmaceutical Chemistry, University of Naples 'Federico II', Italy
Department of Nuclear Medicine, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione 'G. Pascale', Italy
Department of Experimental Pharmacology, University of Naples 'Federico II', Napoli, Italy
References:
Chabner, B.A., Allegra, C.J., Curt, G.A., Calabresi, P., Antineoplastic agents (1996) Goodman and Gillman's The Pharmacological Basis of Therapeutics, p. 1265. , Hardman JG, Limbird LE, editors. 9th ed. New York: McGraw-Hil
Hortobagyi, G.N., Anthracyclines in the treatment of cancer: An overview (1997) Drugs., 54 (SUPPL. 4), pp. 1-7
Gabizon, A., Martin, F., Polyethylene glycol-coated (pegylated) liposomal doxorubicin: Rationale for use in solid tumours (1997) Drugs., 54 (SUPPL. 4), pp. 15-21
Gabizon, A., Pharmacokinetics of PEGylated liposomal doxorubicin (2003) Clin Pharmacokinet., 42, pp. 419-436
Abraham, S.A., Waterhouse, D.N., Lawrence, D., The liposomal formulation of doxorubicin (2005) Methods Enzymol., 391, pp. 71-97
Tardi, P.G., Boman, N.L., Cullis, P.R., Liposomal doxorubicin (1996) J Drug Target., 4, pp. 129-140
Brown, J.M., Giaccia, A.J., The unique physiology of solid tumours: Opportunities (and problems) for cancer therapy (1998) Cancer Res., 58, pp. 408-1416
Gabizon, A., Catane, R., Uziely, B., Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in poly-ethylene-glycol coated liposomes (1994) Cancer Res., 54, pp. 987-992
Gaber, M.H., Wu, N.Z., Hong, K., Huang, S.K., Dewhirst, M.W., Papahadjopoulos, D., Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks (1996) Int J Radiat Oncol Biol Phys., 36, pp. 1177-1187
Matsumura, Y., Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs (1986) Cancer Res., 46, pp. 6387-6392
Marcucci, F., Lefoulon, F., Active targeting with particulate drug carriers in tumor therapy: Fundamentals and recent progress (2004) Drug Discov Today., 9 (5), pp. 219-228
Torchilin, V.P., Antibody-modified liposomes for cancer chemotherapy (2008) Expert Opin Drug Deliv., 5 (9), pp. 1003-1025
Sofou, S., Sgouros, G., Antibody-targeted liposomes in cancer therapy and imaging (2008) Expert Opin Drug Deliv., 5 (2), pp. 189-204
Wu, H.-C., Chang, D.-K., Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy (2010) J Oncol., 2010, pp. 1-8
Reubi, J.C., Waser, B., Schaer, J.C., Laissue, J.A., Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) Eur J Nucl Med., 28 (7), pp. 836-846
Virgolini, I., Raderer, M., Kurtaran, A., Vasoactive intestinal peptidereceptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors (1994) N Engl J Med., 331, pp. 1116-1121
Behr, T.M., Jenner, N., Radetzky, S., Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin (1998) Eur J Nucl Med., 25 (4), pp. 424-430
Breeman, W.A., de Jong, M., Erion, J.L., Preclinical comparison of 111 In-labeled DTPA-or DOTA-bombesin analogs for receptortargeted scintigraphy and radionuclide therapy (2002) J Nucl Med., 43, pp. 1650-1656
Behr, T.M., Gotthardt, M., Barth, A., Behe, M., Imaging tumors with peptidebased radioligands (2001) Q J Nucl Med., 45 (2), pp. 189-200
Accardo, A., Morisco, A., Tesauro, D., Pedone, C., Morelli, G., Naposomes: A new class of peptide derivatized target selective multimodal nanoparticles for imaging and therapeutic applications (2011) Ther Deliv., 2 (2), pp. 235-257
Accardo, A., Tesauro, D., Aloj, L., Peptide containing aggregates as selective nanocarriers for therapeutics (2008) Chem Med Chem., 3, pp. 594-602
Morisco, A., Accardo, A., Tesauro, D., Palumbo, R., Benedetti, E., Morelli, G., Peptide-labeled supramolecular aggregates as selective doxorubicin carriers for delivery to tumor cells (2011) Biopolymers., 96 (1), pp. 88-96
Vaccaro, M., Mangiapia, G., Paduano, L., Structural and relaxometric characterization of peptide aggregates containing gadolinium complexes as potential selective contrast agents in MRI (2007) Chem Phys Chem., 8, pp. 2526-2538
Ding, N., Lu, Y., Lee, R.J., Folate receptor-targeted fluorescent paramagnetic bimodal liposomes for tumor imaging (2011) Int J Nanomedicine., 6, pp. 2513-2520
Lammers, T., Aime, S., Hennink, W.E., Storm, G., Kiessling, F., Theranostic nanomedicines (2011) Acc Chem Res., 44 (10), pp. 1029-1038
Accardo, A., Mansi, R., Morisco, A., Peptide modified nanocarriers for selective targeting of bombesin receptors (2010) Mol Biosyst., 6, pp. 878-887
Markwalder, R., Reubi, J.C., Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation (1999) Cancer Res., 59, pp. 1152-1159
Gugger, M., Reubi, J.C., GRP receptors in non-neoplastic and neoplastic human breast (1999) Am J Pathol., 155, pp. 2067-2076
Fleischmann, A., Waser, B., Reubi, J.C., Overexpression of gastrin-releasing peptide receptors in tumor-associated blood vessels of human ovarian neoplasms (2007) Cell Oncol., 29, pp. 421-433
Smith, C.J., Volkert, W.A., Hoffman, T.J., Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes (2005) Nucl Med Biol., 32, pp. 733-740
Rogers, B.E., Bigott, H.M., McCarthy, D.W., MicroPET Imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue (2003) Bioconjugate Chem., 14 (4), pp. 756-763
Parry, J.J., Kelly, T.S., Andrews, R., Rogers, B.E., In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin(7-14) analogues containing different amino acid linker moieties (2007) Bioconjugate Chem., 18 (4), pp. 1110-1117
Schmitt, L., Dietrich, C., Synthesis and characterization of chelator-lipids for reversible immobilization of engineered proteins at self-assembled lipid interfaces (1994) J Am Chem Soc., 116 (19), pp. 8485-8491
Chang, W.C., White, P.D., (2000) Fmoc Solid Phase Peptide Synthesis., , Oxford, UK: Oxford Univ Press
Stewart, J.C.M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate (1980) Anal Biochem., 104, pp. 10-14
Allen, T.M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo (1991) Biochim Biophys Acta Biomembranes., 1066 (1), pp. 29-36
Fritze, A., Hens, F., Kimpfler, A., Schubert, R., Peschka-Süss, R., Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient (2006) Biochimica et Biophysica Acta., 1758 (10), pp. 1633-1640
An, Z., Wang, X., Geller, J., Moossa, A.R., Hoffman, R.M., Surgical orthotopic implantation allows high lung and lymph node metastatic expression of human prostate carcinoma cell line PC-3 in nude mice (1998) Prostate., 34 (3), pp. 169-174
Fridman, R., Kibbey, M.C., Royce, L.S., Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel (1991) J Natl Cancer Inst., 83 (11), pp. 769-774
Xie, J., Lee, S., Chen, X., Nanoparticle-based theranostic agents (2010) Adv Drug Deliv Rev., 62, pp. 1064-1079
Chabner, B. A., Allegra, C. J., Curt, G. A., Calabresi, P., Antineoplastic agents (1996) Goodman and Gillman's The Pharmacological Basis of Therapeutics, p. 1265. , Hardman JG, Limbird LE, editors. 9th ed. New York: McGraw-Hil
Hortobagyi, G. N., Anthracyclines in the treatment of cancer: An overview (1997) Drugs., 54 (SUPPL. 4), pp. 1-7
Abraham, S. A., Waterhouse, D. N., Lawrence, D., The liposomal formulation of doxorubicin (2005) Methods Enzymol., 391, pp. 71-97
Tardi, P. G., Boman, N. L., Cullis, P. R., Liposomal doxorubicin (1996) J Drug Target., 4, pp. 129-140
Brown, J. M., Giaccia, A. J., The unique physiology of solid tumours: Opportunities (and problems) for cancer therapy (1998) Cancer Res., 58, pp. 408-1416
Gaber, M. H., Wu, N. Z., Hong, K., Huang, S. K., Dewhirst, M. W., Papahadjopoulos, D., Thermosensitive liposomes: Extravasation and release of contents in tumor microvascular networks (1996) Int J Radiat Oncol Biol Phys., 36, pp. 1177-1187
Torchilin, V. P., Antibody-modified liposomes for cancer chemotherapy (2008) Expert Opin Drug Deliv., 5 (9), pp. 1003-1025
Wu, H. -C., Chang, D. -K., Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy (2010) J Oncol., 2010, pp. 1-8
Reubi, J. C., Waser, B., Schaer, J. C., Laissue, J. A., Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands (2001) Eur J Nucl Med., 28 (7), pp. 836-846
Behr, T. M., Jenner, N., Radetzky, S., Targeting of cholecystokinin-B/ gastrin receptors in vivo: Preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin (1998) Eur J Nucl Med., 25 (4), pp. 424-430
Breeman, W. A., de Jong, M., Erion, J. L., Preclinical comparison of 111 In-labeled DTPA-or DOTA-bombesin analogs for receptortargeted scintigraphy and radionuclide therapy (2002) J Nucl Med., 43, pp. 1650-1656
Behr, T. M., Gotthardt, M., Barth, A., Behe, M., Imaging tumors with peptidebased radioligands (2001) Q J Nucl Med., 45 (2), pp. 189-200
Smith, C. J., Volkert, W. A., Hoffman, T. J., Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes (2005) Nucl Med Biol., 32, pp. 733-740
Rogers, B. E., Bigott, H. M., McCarthy, D. W., MicroPET Imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue (2003) Bioconjugate Chem., 14 (4), pp. 756-763
Parry, J. J., Kelly, T. S., Andrews, R., Rogers, B. E., In vitro and in vivo evaluation of 64Cu-labeled DOTA-linker-bombesin (7-14) analogues containing different amino acid linker moieties (2007) Bioconjugate Chem., 18 (4), pp. 1110-1117
Chang, W. C., White, P. D., (2000) Fmoc Solid Phase Peptide Synthesis., , Oxford, UK: Oxford Univ Press
Stewart, J. C. M., Colorimetric determination of phospholipids with ammonium ferrothiocyanate (1980) Anal Biochem., 104, pp. 10-14
Allen, T. M., Hansen, C., Martin, F., Redemann, C., Yau-Young, A., Liposomes containing synthetic lipid derivatives of poly (ethylene glycol) show prolonged circulation half-lives in vivo (1991) Biochim Biophys Acta Biomembranes., 1066 (1), pp. 29-36
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent
Objectives: Drug delivery systems consisting of liposomes displaying a cell surface receptor-targeting peptide are being developed to specifically deliver chemotherapeutic drugs to tumors overexpressing a target receptor. This study addresses novel liposome composition approaches to specifically target tissues overexpressing bombesin (BN) receptors. Methods: A new amphiphilic peptide derivative (MonY-BN) containing the BN(7-14) peptide, the DTPA (diethylenetriaminepentaacetate) chelating agent, a hydrophobic moiety with two C18 alkyl chains, and polyethylene glycol spacers, has been synthesized by solid-phase methods. Liposomes have been generated by co-aggregation of MonY-BN with 1,2-distearoyl-sn-glycero- 3-phosphocholine (DSPC). The structural and biological properties of these new target-selective drug-delivery systems have been characterized. Results: Liposomes with a DSPC/MonY-BN (97/3 molar ratio) composition showed a diameter of 145.5±31.5 nm and a polydispersity index of 0.20 ± 0.05. High doxorubicin (Dox) loading was obtained with the remote pH gradient method using citrate as the inner buffer. Specific binding to PC-3 cells of DSPC/MonY-BN liposomes was obtained (2.7% ± 0.3%, at 37°C), compared with peptide-free DSPC liposomes (1.4% ± 0.2% at 37°C). Incubation of cells with DSPC/ MonY-BN/Dox showed significantly lower cell survival compared with DSPC/Dox-treated cells, in the presence of 100 ng/mL and 300 ng/mL drug amounts, in cytotoxicity experiments. Intravenous treatment of PC-3 xenograft-bearing mice with DSPC/MonY-BN/Dox at 10 mg/kg Dox dose produced higher tumour growth inhibition (60%) compared with nonspecific DSPC/ Dox liposomes (36%) relative to control animals. Conclusion: The structural and loading properties of DSPC/MonY-BN liposomes along with the observed in-vitro and in-vivo activity are encouraging for further development of this approach for target-specific cancer chemotherapy. © 2012 Accardo et al, publisher and licensee Dove Medical Press Ltd.
Objectives: Drug delivery systems consisting of liposomes displaying a cell surface receptor-targeting peptide are being developed to specifically deliver chemotherapeutic drugs to tumors overexpressing a target receptor. This study addresses novel liposome composition approaches to specifically target tissues overexpressing bombesin (BN) receptors. Methods: A new amphiphilic peptide derivative (MonY-BN) containing the BN(7-14) peptide, the DTPA (diethylenetriaminepentaacetate) chelating agent, a hydrophobic moiety with two C18 alkyl chains, and polyethylene glycol spacers, has been synthesized by solid-phase methods. Liposomes have been generated by co-aggregation of MonY-BN with 1,2-distearoyl-sn-glycero- 3-phosphocholine (DSPC). The structural and biological properties of these new target-selective drug-delivery systems have been characterized. Results: Liposomes with a DSPC/MonY-BN (97/3 molar ratio) composition showed a diameter of 145.5±31.5 nm and a polydispersity index of 0.20 ± 0.05. High doxorubicin (Dox) loading was obtained with the remote pH gradient method using citrate as the inner buffer. Specific binding to PC-3 cells of DSPC/MonY-BN liposomes was obtained (2.7% ± 0.3%, at 37°C), compared with peptide-free DSPC liposomes (1.4% ± 0.2% at 37°C). Incubation of cells with DSPC/ MonY-BN/Dox showed significantly lower cell survival compared with DSPC/Dox-treated cells, in the presence of 100 ng/mL and 300 ng/mL drug amounts, in cytotoxicity experiments. Intravenous treatment of PC-3 xenograft-bearing mice with DSPC/MonY-BN/Dox at 10 mg/kg Dox dose produced higher tumour growth inhibition (60%) compared with nonspecific DSPC/ Dox liposomes (36%) relative to control animals. Conclusion: The structural and loading properties of DSPC/MonY-BN liposomes along with the observed in-vitro and in-vivo activity are encouraging for further development of this approach for target-specific cancer chemotherapy. © 2012 Accardo et al, publisher and licensee Dove Medical Press Ltd.
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent
No results. |
Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: A potential theranostic agent
Other filter: ([btitle,keywords] "Bombesin Peptide" OR ...
Fik-jaskółka MA, Mkrtchyan AF, Saghyan AS, Palumbo R, Belter A, Hayriyan LA, Simonyan H, Roviello V, Roviello GN
* Spectroscopic and SEM evidences for G4-DNA binding by a synthetic alkyne-containing amino acid with anticancer activity (209 views) (PDF 75 views)
Spectrochim Acta A (ISSN: 1386-1425linking), 2020 Mar 15; 229: 117884-117884.
Impact Factor: 3.232
View Export to BibTeX Export to EndNote
Carella A, Roviello V, Iannitti R, Palumbo R, La Manna S, Marasco D, Trifuoggi M, Diana R, Roviello GN
* Evaluating the biological properties of synthetic 4-nitrophenyl functionalized benzofuran derivatives with telomeric DNA binding and antiproliferative activities (397 views)
Int J Biol Macromol (ISSN: 0141-8130linking, 1879-0003electronic), 2019 Jan; 121: 77-88.
Impact Factor: 4.784
View Export to BibTeX Export to EndNote
Longo DL, Stefania R, Aime S, Oraevsky A
* Melanin-Based Contrast Agents for Biomedical Optoacoustic Imaging and Theranostic Applications (319 views)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2017 Aug 7; 18(8): N/D-N/D.
Impact Factor: 3.687
View Export to BibTeX Export to EndNote
Ringhieri P, Iannitti R, Nardon C, Palumbo R, Fregona D, Morelli G, Accardo A
* Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes (473 views)
Int J Pharm (ISSN: 0378-5173, 1873-3476), 2014 Oct 1; 473(1-2): 194-202.
Impact Factor: 3.65
View Export to BibTeX Export to EndNote
Accardo A, Mansi R, Salzano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Ziaco B, Tesauro D, Aloj L, De Rosa G, Morelli G
* Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells (410 views)
Journal Of Drug Targeting (ISSN: 1061-186x), 2012 Nov 21; 21(3): 240-249.
Impact Factor: 2.768
View Export to BibTeX Export to EndNote
* Spectroscopic and SEM evidences for G4-DNA binding by a synthetic alkyne-containing amino acid with anticancer activity (209 views) (PDF 75 views)
Spectrochim Acta A (ISSN: 1386-1425linking), 2020 Mar 15; 229: 117884-117884.
Impact Factor: 3.232
View Export to BibTeX Export to EndNote
Carella A, Roviello V, Iannitti R, Palumbo R, La Manna S, Marasco D, Trifuoggi M, Diana R, Roviello GN
* Evaluating the biological properties of synthetic 4-nitrophenyl functionalized benzofuran derivatives with telomeric DNA binding and antiproliferative activities (397 views)
Int J Biol Macromol (ISSN: 0141-8130linking, 1879-0003electronic), 2019 Jan; 121: 77-88.
Impact Factor: 4.784
View Export to BibTeX Export to EndNote
Longo DL, Stefania R, Aime S, Oraevsky A
* Melanin-Based Contrast Agents for Biomedical Optoacoustic Imaging and Theranostic Applications (319 views)
Int J Mol Sc (ISSN: 1422-0067, 1661-6596, 1422-0067linking), 2017 Aug 7; 18(8): N/D-N/D.
Impact Factor: 3.687
View Export to BibTeX Export to EndNote
Ringhieri P, Iannitti R, Nardon C, Palumbo R, Fregona D, Morelli G, Accardo A
* Target selective micelles for bombesin receptors incorporating Au(III)-dithiocarbamato complexes (473 views)
Int J Pharm (ISSN: 0378-5173, 1873-3476), 2014 Oct 1; 473(1-2): 194-202.
Impact Factor: 3.65
View Export to BibTeX Export to EndNote
Accardo A, Mansi R, Salzano G, Morisco A, Aurilio M, Parisi A, Maione F, Cicala C, Ziaco B, Tesauro D, Aloj L, De Rosa G, Morelli G
* Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells (410 views)
Journal Of Drug Targeting (ISSN: 1061-186x), 2012 Nov 21; 21(3): 240-249.
Impact Factor: 2.768
View Export to BibTeX Export to EndNote
5 Records (5 excluding Abstracts).
Total impact factor: 18.121 (18.121 excluding Abstracts).
Total 5 year impact factor: 18.186 (18.186 excluding Abstracts).
Total impact factor: 18.121 (18.121 excluding Abstracts).
Total 5 year impact factor: 18.186 (18.186 excluding Abstracts).
381 views. Last view on Saturday 25 February 2023, 9:50:41
ibb.cnr.it
